EVERYTHING XIAOMI
Get listed
Side by side

Covidence vs Rayyan

Covidence

6.4#13 in systematic review softwareFrom $339 a year
Web
Visit
Rayyan logo

Rayyan

7.5#3 in ai literature review softwareFrom $4.99 a month
Free planAndroidiOSWebAPI
Visit

What both publish

FactCovidenceRayyan
HeadquartersMelbourne, AustraliaCambridge, Massachusetts, USA
IntegrationsCovidence lists CRS, EndNote, Zotero, RefWorks, Mendeley, RevMan, and tools supporting RIS, CSV, or PubMedXML formats as compatible workflow tools.Rayyan accepts exported reference files from external databases and reference managers; it says there is no direct database connection.
PurposeCovidence is a non-profit platform that helps researchers systematically review research.Rayyan is a systematic review platform for teams conducting transparent, auditable, and reproducible evidence reviews.
SecurityCovidence says it uses industry-standard encryption to store and transfer personal data and operates as a cloud-based service where data may be stored outside a user's country.Rayyan's enterprise page states HIPAA and GDPR compliance, SOC 2 controls, encryption in transit and at rest, and support for SAML 2.0, OAuth, and MFA.
SupportThe contact page says the support team usually replies within one business day; pricing also includes free online technical support.The pricing page lists Standard support for Free and Essential, priority support for Advanced and Business / Academic, and dedicated support for Enterprise.

Covidence plans

  • Single$339 a year
  • Package$907 a year
  • InstitutionsPriced on request

Rayyan plans

  • FreeFree
  • Essential$4.99 a month
  • Advanced$8.33 a month
  • Business / Academic$41.67 a month
  • EnterprisePriced on request

Pick Covidence if…

You want what its maker publishes above — check its page for the details.

Pick Rayyan if…

It suits research teams screening and analysing evidence across a systematic review workflow. The intended organisation users include pharma, medical-device, CRO, university, healthcare, government, and health technology assessment teams.

Charts they share